Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983807 | 0.93 | PIK3CD (0.35) | KCNH2PIK3CDPTGS1PTGS2CNR1 | |
| SCHEMBL30983829 | 0.90 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31269215 | 0.90 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31269475 | 0.88 | PIK3CD (0.37) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268930 | 0.88 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL31269380 | 0.88 | PDE2A (0.38) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269136 | 0.88 | PIK3CD (0.36) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL30983456 | 0.88 | PIK3CD (0.35) | KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269054 | 0.87 | KCNH2 (0.34) | KCNH2SCN5ASCN9APIK3CDCNR1 | |
| SCHEMBL30983776 | 0.87 | PIK3CD (0.40) | PIK3CDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | KCNH2 2824/4885SCN5A 1800/4885SCN9A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.